Jefferies downgrades Artiva Biotherapeutics to Hold from Buy, sets price target at $4

Jefferies downgraded Artiva Biotherapeutics to Hold from Buy, setting a $4 price target. This implies a 5.4% downside from the Oct 29 close of $4.23. Recent analyst price targets for the company range from $4 to $40.

Original reporting
Published Oct 29, 2026, 10:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 10:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Jefferies downgrades Artiva Biotherapeutics to Hold from Buy, sets price target at $4 — source image
Decision brief

The 30-second read

$ARTVBearishMed
01

Why it matters

For traders, the key actionable element is the downgrade plus a specific lower price target, which can affect positioning, options pricing, and near-term sentiment even without new fundamental data.

02

Market read

A single-name sell-side downgrade with a lower target can move the stock on sentiment, but the article provides no new clinical or regulatory datapoint.

03

What to watch

The brief does not include Jefferies’ rationale, any changes to clinical/regulatory outlook, or probability updates, which are typically what drive sustained repricing.

Relevance 6/10Novelty 6/10Timing: after-hours/overnight analyst note impact, before next session

Background

The piece summarizes a Jefferies rating change and notes that recent analyst targets for Artiva have varied widely over the past month.

Company-level read

Ticker impact

$ARTVBearishMedium confidence
Context

Jefferies downgraded Artiva Biotherapeutics to Hold from Buy and set a $4 price target, implying downside from the Oct 29 close.

Expected impact

Likely downward pressure as the market incorporates the downgrade and the lower $4 target into expectations.

Evidence & confidence

The article provides a concrete rating change and a specific new target, but it lacks the underlying thesis or any new company-specific operational/clinical catalyst.

Market effects

Adds incremental bearish sentiment to small-cap biotech risk appetite, though it is single-name and not a sector-wide catalyst.

No clear regional spillover beyond US small-cap biotech sentiment.

Limited global relevance; this is a US analyst action on a single issuer.

Counterpoint

The wide range of recent price targets ($4 to $40) suggests high uncertainty; the downgrade may be less informative if the market discounts analyst dispersion.

Key entities

  • Artiva Biotherapeutics

    Subject of the Jefferies downgrade to Hold from Buy and new $4 price target.

  • Jefferies

    Brokerage issuing the downgrade and price target.

Related articles

Low

Artiva Ends AlloNK Autoimmune Cell Therapy After Two Trial Deaths, One Unexplained, and Cuts 94% of Staff

Artiva Biotherapeutics halted its AlloNK cell therapy trial for autoimmune diseases after two participant deaths, one linked to chemotherapy. The company will cut 94% of its staff and explore strategic options, including a sale or dissolution. AlloNK was tested with rituximab in rheumatoid arthritis and other autoimmune diseases. Artiva reported $319.1 million in cash as of September 30.

$ARTVMed

Jefferies downgrades Artiva Biotherapeutics stock rating to hold

Jefferies downgraded Artiva Biotherapeutics (ARTV) to Hold with a $4.00 price target after the company discontinued its AlloNK program due to safety concerns and lack of long-term efficacy in rheumatoid arthritis patients. The stock is down 31% over the past week. The company is cutting 94% of staff and exploring strategic alternatives, though it has strong short-term liquidity. Analysts have mixed views, with some maintaining bullish ratings and high price targets.

MedAI 8/10

Patients Deaths and Data Shortfall Spell the End for Cell Therapy Biotech Artiva

Artiva Biotherapeutics is halting its lead cell therapy program, AlloNK, after two patient fatalities in a mid-stage trial and updated clinical data raising concerns about its efficacy. The company will lay off 94% of its staff and has $319.1 million in cash. Analysts note potential implications for Nkarta and Fate Therapeutics, with Nkarta's upcoming data presentation under scrutiny.